» Articles » PMID: 372242

Recovery of Endothelial Cell Prostacyclin Production After Inhibition by Low Doses of Aspirin

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1979 Mar 1
PMID 372242
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Endothelial cells synthesize prostacyclin (PGI(2)), an unstable prostaglandin that inhibits platelet aggregation and serotonin release. Because cyclooxygenase, which is necessary for synthesis of PGI(2), is inactivated by aspirin, we examined the effect of aspirin on PGI(2) production by cultured human endothelial cells. Endothelial cells synthesize PGI(2) (20.1+/-7.2 ng/10(6) cells, mean+/-SD) when stimulated with 20 muM sodium arachidonate for 2 min. PGI(2) production is inhibited by low-dose aspirin (5 muM); the t((1/2)) of inactivation is 6.0+/-1.3 min (mean+/-SEM, n = 3). Thus, endothelial cell cyclooxygenase is as sensitive to aspirin as the enzyme in platelets. After 1 h incubation with aspirin, endothelial cell PGI(2) production was inhibited 50% by 2.1+/-0.4 muM aspirin and was inhibited 90% by 6.2+/-0.9 muM aspirin (mean+/-SEM, n = 4). When endothelial cells were incubated with 100 muM aspirin, washed, and recultured, their ability to synthesize PGI(2) returned to control levels in 35.6+/-1.0 h (mean+/-SEM, n = 4). Recovery of endothelial PGI(2) production after aspirin depended on de novo protein synthesis because treatment with cycloheximide (3 mug/ml) inhibited recovery by 92%.These results indicate that although endothelial cell cyclooxygenase in vitro is inhibited by low concentrations of aspirin, endothelial cells rapidly resynthesize their cyclooxygenase after the aspirin is removed. This rapid resynthesis of cyclooxygenase lessens the likelihood that aspirin used in clinical doses promotes thrombosis.

Citing Articles

Should aspirin be replaced with ADP blockers and anti-GPVI to manage thrombosis?.

Khan H, Ghulam T, Ahmed N, Rafai Babar M, Calaminus S, Zuhair Yusuf M Vasc Biol. 2023; 5(1).

PMID: 37931411 PMC: 9986383. DOI: 10.1530/VB-22-0010.


Low-dose aspirin was associated with an increased risk of cardiovascular events in patients with chronic kidney disease patients and low bodyweight: results from KNOW-CKD study.

Oh Y, Kim A, Ro H, Chang J, Lee H, Chung W Sci Rep. 2021; 11(1):6691.

PMID: 33758303 PMC: 7988000. DOI: 10.1038/s41598-021-86192-4.


Identification of a homozygous recessive variant in resulting in a congenital aspirin-like defect in platelet function.

Chan M, Hayman M, Sivapalaratnam S, Crescente M, Allan H, Edin M Haematologica. 2020; 106(5):1423-1432.

PMID: 32299908 PMC: 8094108. DOI: 10.3324/haematol.2019.235895.


Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1.

Li C, Raikwar N, Santillan M, Santillan D, Thomas C Placenta. 2015; 36(4):446-53.

PMID: 25638730 PMC: 4359945. DOI: 10.1016/j.placenta.2015.01.004.


Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes.

Thomas M, Storey R J Cardiovasc Transl Res. 2013; 7(1):19-28.

PMID: 24309957 DOI: 10.1007/s12265-013-9524-6.


References
1.
Gorman R, Bunting S, MILLER O . Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins. 1977; 13(3):377-88. DOI: 10.1016/0090-6980(77)90018-1. View

2.
Livio M, Villa S, de Gaetano G . Aspirin, thromboxane, and prostacyclin in rats: A dilemma resolved?. Lancet. 1978; 1(8077):1307. DOI: 10.1016/s0140-6736(78)91286-2. View

3.
Tateson J, Moncada S, Vane J . Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins. 1977; 13(3):389-97. DOI: 10.1016/0090-6980(77)90019-3. View

4.
Burch J, Stanford N, MAJERUS P . Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest. 1978; 61(2):314-9. PMC: 372541. DOI: 10.1172/JCI108941. View

5.
Weksler B, Ley C, Jaffe E . Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A 23187. J Clin Invest. 1978; 62(5):923-30. PMC: 371849. DOI: 10.1172/JCI109220. View